In this prospective cohort study, we measured admission anti-PS and anti-DNA autoantibodies in Ugandan children with SM and evaluated whether autoantibodies were associated with disease severity and outcomes over two years follow-up. This evidence concerns the gene PRB2 and systemic mastocytosis.